Incyte Corporation

2026-06-13 15:14:52

Incyte announced positive data from Phase 1 studies of INCA033989, a novel antibody for myelofibrosis (MF) and essential thrombocythemia (ET), demonstrating rapid and sustained clinical and molecular responses. The drug effectively reduced spleen volume, improved symptoms, and normalized platelet counts, alongside lowering mutant CALR variant allele frequency. These findings support INCA033989's potential for disease modification and prompt the initiation of a pivotal Phase 3 study for ET.

2026-06-13 10:07:51

Incyte announced positive results from its pivotal Phase 3 frontMIND trial, demonstrating that the combination of tafasitamab and lenalidomide with R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The Tafa-Len-R-CHOP regimen reduced the risk of disease progression or death by 25% compared to R-CHOP alone and was generally well-tolerated. These findings, presented at the EHA 2026 Congress Plenary, support global regulatory applications for this combination as a potential new first-line standard of care.

2026-06-13 10:02:54

Incyte announced positive results from its pivotal Phase 3 frontMIND trial, showing that the tafasitamab (Monjuvi/Minjuvi) combination therapy significantly prolonged progression-free survival in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The treatment reduced the risk of disease progression or death by 25% and was generally well-tolerated. These results support global regulatory applications for the therapy as a potential new standard of care.

2026-06-12 18:39:45

AbCellera Biologics recently appointed Victor Sandor, an experienced oncology drug developer, to its Board of Directors. This move is seen as potentially strengthening investor confidence in AbCellera's clinical and regulatory capabilities, especially as the company transitions from a discovery platform to a clinical-stage biotech. Sandor's expertise is expected to complement AbCellera's efforts to advance assets like ABCL635 amidst ongoing net losses and significant R&D investment.

2026-06-12 12:02:50

This "Rx Rundown" details significant medical marketing news, dealmaking, and industry chatter for the week. Key highlights include major acquisitions and collaborations by pharmaceutical giants like Incyte, Johnson & Johnson, and Roche, alongside FDA approvals for treatments from Pfizer, Lilly, and Takeda. The report also covers substantial funding rounds for biopharmaceutical companies, some layoffs, and crucial industry news including clinical trial results and regulatory updates.

2026-06-12 11:37:49

Sector Gamma AS increased its stake in Incyte Corporation (NASDAQ:INCY) by 6.7% in the fourth quarter, purchasing an additional 13,669 shares bringing their total holdings to 218,783 shares valued at approximately $21.6 million. Institutional investors collectively own 96.97% of Incyte's stock, with other major firms like Geode Capital Management and LSV Asset Management also adding to their positions. Despite mixed analyst ratings with a consensus "Hold" and an average price target of $105.10, Incyte recently surpassed earnings expectations with $1.81 EPS and 20.9% revenue growth year-over-year.